XML 53 R41.htm IDEA: XBRL DOCUMENT v3.19.1
LONG-TERM DEBT (Tables)
 9 Months Ended
Apr. 27, 2019
Debt Disclosure [Abstract]  
Schedule of Debt
The Company’s long-term debt consisted of the following:
(in thousands)
Average Interest Rate at
January 26, 2019
 
Maturity Year
 
April 27,
2019
 
July 28,
2018
Term Loan Facility
6.64%
 
2019-2025
 
$
1,888,800

 
$
—

ABL Credit Facility
4.07%
 
2023
 
1,217,100

 
—

Other secured loans
5.70%
 
2023
 
45,710

 
—

Former ABL Credit Facility
 
 
 
 
—

 
210,000

Former Term Loan Facility
 
 
 
 
—

 
110,000

Debt issuance costs, net
 
 
 
 
(57,608
)
 
(1,164
)
Original issue discount on debt
 
 
 
 
(42,729
)
 
—

Long-term debt, including current portion
 
 
 
 
$
3,051,273

 
$
318,836

Less: current portion of long-term debt obligations
 
 
 
 
(107,281
)
 
(10,000
)
Long-term debt
 
 
 
 
$
2,943,992

 
$
308,836
Schedule of Line of Credit Facility
The assets included in the Condensed Consolidated Balance Sheets securing the outstanding borrowings under the ABL Credit Facility on a first-priority basis, and the unused available credit and fees under the ABL Credit Facility, were as follows:
Assets securing the ABL Credit Facility (in thousands)(1):
April 27, 2019
Certain inventory assets included in Inventories and Current assets of discontinued operations
$
2,276,895

Certain receivables included in Receivables and Current assets of discontinued operations
$
917,296

(1)
The ABL Credit Facility is also secured by all of the Company’s pharmacy scripts, which are included in Long-term assets of discontinued operations in the Condensed Consolidated Balance Sheets as of April 27, 2019.
Unused available credit and fees under the ABL Credit Facility (in thousands, except percentages):
April 27, 2019
Outstanding letters of credit
$
80,606

Letter of credit fees
1.625
%
Unused available credit
$
791,352

Unused facility fees
0.25
%